Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Family Blood Pressure Program - GENOA (Genetic Epidemiology Network of Atherosclerosis)

This study has been terminated.
Sponsor:
Collaborator:
Information provided by:
The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT00234260
First received: October 4, 2005
Last updated: July 15, 2008
Last verified: October 2005
  Purpose

GENOA, the Genetic Epidemiology Network of Arteriopathy, consists of a network of three field centers and biochemical and genetic core labs to study the common polymorphic genetic variations to determine individual differences in blood pressure and essential hypertension in 1,500 sibling pairs in three racial groups. Linkage analyses are performed using an extensive array of candidate genes and anonymous markers throughout the genome.


Condition
Arteriosclerosis
Hypertension
Heart Diseases

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Family Blood Pressure Program - GENOA (Genetic Epidemiology Network of Atherosclerosis)

Resource links provided by NLM:


Further study details as provided by The University of Texas Health Science Center, Houston:

Study Start Date: April 1995
Detailed Description:

Each collaborating investigator is responsible for an essential element of the network: Eric Boerwinkle for genotyping and linkage analyses, Robert Ferrell for genotyping, Craig Hanis for recruiting Mexican-Americans, Richard Hutchinson for recruiting African-Americans, Sharon Kardia for cladistic and prediction analyses and data management, and Stephen Turner for recruiting Non-Hispanic whites and measuring physiologic variables. Between 1995 and 2000, the network carried out five specific aims to localize and characterize the genetic determinants of high blood pressure. Aim 1 used robust sibling pair linkage methods in 500 hypertensive sibling pairs in each racial group (a total of 1,500 sibling pairs) to localize genes influencing interindividual differences in the occurrence of essential hypertension. Aims 2 and 3 took advantage of previously collected blood pressure and intermediate predictor trait data from 1,488 normotensive sibling pairs from the Rochester Family Heart Study to localize genes contributing to essential hypertension. The linkage analyses (Aims 1-3) used both an extensive array of candidate genes and a large number of anonymous markers throughout the genome. Aim 4 used multiple diallelic sequence polymorphisms and cladistic analyses within a linked gene to identify haplotypes for further DNA sequencing in order to identify candidate functional DNA sequence variation contributing to interindividual differences in BP levels and essential hypertension status. Aim 5 evaluated the ability of candidate functional DNA sequence variation to predict essential hypertension status in the three racial groups.

The study was renewed in September 2000 to pursue two lines of investigation. The first is to identify and characterize genes contributing to atherosclerotic coronary heart disease using electron beam computed tomography (EBCT) to quantify coronary artery calcification as a measure of preclinical disease. Robust sibling-pair linkage methods will be used to determine whether any of the more than 375 highly polymorphic tandem repeat marker loci spanning the genome are linked to genes influencing EBCT measures of coronary artery calcification in at least 500 GENOA sibships from Rochester, Minnesota. Association analysis will be used to determine whether biallelic markers of DNA sequence variation in candidate genes identified by GENOA or others to influence blood pressure level or diagnostic category also influence EBCT measures of coronary artery calcification in at least 500 GENOA participants from Rochester, Minnesota. The second line of investigation extends analytical methods (linkage disequilibrium regression and combinatorial partitioning) to more finely localize positional candidate genes and loci, and to identify gene-gene and gene-environment interaction effects influencing the measured Family Blood Pressure Program and GENOA phenotypes.

  Eligibility

Ages Eligible for Study:   up to 64 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

Jackson Mississippi - age 45-64, Hypertensive Rochester, Minnesota - <60, Hypertensive Starr County, Texas - <60, type II diabetes mellitus

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00234260

Locations
United States, Minnesota
Rochester Field Center
Rochester, Minnesota, United States, 55905
United States, Mississippi
Jackson Field Center
Jackson, Mississippi, United States, 39216
United States, Texas
Starr County Field Center
Rio Grande City, Texas, United States, 78588
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Investigators
Principal Investigator: Eric Boerwinkle, PhD Human Genetics Center, The University of Texas at Houston Health Science Center
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00234260     History of Changes
Other Study ID Numbers: U01 HL075572
Study First Received: October 4, 2005
Last Updated: July 15, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by The University of Texas Health Science Center, Houston:
Genetics

Additional relevant MeSH terms:
Arteriosclerosis
Atherosclerosis
Heart Diseases
Hypertension
Arterial Occlusive Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 27, 2014